Scottish Medicines Consortium (SMC) provisionally approves Almirall’s Ilumetri®▼ (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis

Final SMC approval is expected in October 2019 From this date, dermatologists in Scotland will have an additional biologic treatment option and suitable patients can be considered for treatment Tildrakizumab is a high-affinity humanized monoclonal antibody that inhibits the p19 subunit of IL-23 1 , that has demonstrated lasting efficacy and safety through 3 years according to the positive results of a pooled analysis 2 of two phase III clinical trials Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states

The release as fetched from its publisher. almirall.com ↗